Therapeutic Response

ABL1 p.T315I and BCR::ABL1 status confers therapeutic sensitivity to Ponatinib in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Iclusig (ponatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.
Iclusig (ponatinib) [product monograph]. HC. Health Canada approved ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.